Trial intelligence / Profile preview

Phase III trial of Hexaxim vs Infanrix hexa in Thai infants

2011-004457-87Phase 3

Sponsor
Sanofi
Start
Apr 2012
Modality
Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 3, randomised, single-blind trial of hexaxim in diphtheria, Tetanus, pertussis and 3 more (2 arms), sponsored by Sanofi. Primary endpoint: Primary seroprotection rates for hepatitis B and PRP.

02

Drugs

hexaxim
03

Conditions

diphtheriaTetanuspertussispoliomyelitisHaemophilus influenzae type b disease (Hib)

Beyond the preview

Go deeper on 2011-004457-87.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2011-004457-87.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call